A Prototype Expert System for the Selection of Road Construction Materials

A prototype for an expert system in road construction material selection system, which is based on the outcomes of Friedman and multiple comparisons statistical methods was developed. The outcomes were acquired through questionnaires from selected pavement experts. The factors affecting pavement materials under each particular site condition were incorporated into the specific rules of the system. The system knowledge-base was extracted from the statistical testing outcomes and then rearranged and compiled prior to the development of the system. Visual Basic 6.0 was adopted as the programming tool for development of the system, while the knowledge-base of the separate system was kept in Microsoft Access 2000. The prototype expert system can be used to emulate part of the professional reasoning capabilities based on the knowledge of a pavement expert or a specialist to solve problems on materials selection. The system can help road designers to improve their professional ability to evaluate all available materials even before carrying out any laboratory tests

A piezoelectric energy harvesting interface circuit using one-shot pulse transformer boost converter based on water bucket fountain strategy

Recent advancement in commercial MEMS-based piezoelectric energy harvesters has enabled further reduction of both system cost and size as the device dimension scales down. A nature inspired interface circuit by mimicking water bucket fountain to harvest piezoelectric charge is presented. The proposed architecture offers built-in input voltage protection, harvests electrical energy using minimal switching activity and does not cause mechanical dampening to the piezoelectric cantilever. System simulation and measurement using a standard CMOS 0.13μm process verified the proposed architecture. The pulse transformer boost converter has self-start voltage as low as 45mV and peak efficiency up to 75%, whereas the remaining digital control and voltage processing circuits require less than 1.5μW to operate. © 2014 IEEE

A Prototype Expert System for the Selection of Road Construction Materials

A prototype for an expert system in road construction material selection system, which is based on the outcomes of Friedman and multiple comparisons statistical methods was developed. The outcomes were acquired through questionnaires from selected pavement experts. The factors affecting pavement materials under each particular site condition were incorporated into the specific rules of the system. The system knowledge-base was extracted from the statistical testing outcomes and then rearranged and compiled prior to the development of the system. Visual Basic 6.0 was adopted as the programming tool for development of the system, while the knowledge-base of the separate system was kept in Microsoft Access 2000. The prototype expert system can be used to emulate part of the professional reasoning capabilities based on the knowledge of a pavement expert or a specialist to solve problems on materials selection. The system can help road designers to improve their professional ability to evaluate all available materials even before carrying out any laboratory tests

Mutations in rpoB and fusA cause resistance to rifampicin and fusidic acid in methicillin-resistant Staphylococcus aureus strains from a tertiary hospital in Malaysia

Abstract Background The prevalence of resistance to rifampicin and fusidic acid among Malaysian strains of methicillin-resistant Staphylococcus aureus (MRSA) is increasing. This study aimed to determine the mechanisms of rifampicin and fusidic acid resistance and the genetic diversity of MRSA strains from a Malaysian tertiary hospital. Methods Minimum inhibitory concentrations (MIC) for 21 MRSA strains were determined by agar dilution test and Etest. The resistance genes, staphylococcal chromosome cassette mec (SCCmec) types, multilocus-sequence typing (MLST) types and spa types, were determined by PCR and DNA sequencing. Results MIC for rifampicin and fusidic acid resistance ranged from <1 to 8 µg/ml and from <1 to 256 µg/ml, respectively. A double mutation (484Arg/His and 517Glu/Gln) in rpoB causes high rifampicin resistance while a mutational change (461Leu/Lys) in fusA was observed in seven strains highly resistant to fusidic acid. Five of the seven were also resistant to rifampicin (MIC 8 µg/ml) and carried a mutated rpoB gene (484Arg/His). No other acquired fusidic acid resistance gene (fusB, fusC or fusD) was detected. Most (14/21) of the strains belonged to clone ST239-III-t037. Three belonged to ST22-IV-t1378 and the remaining four to ST239-III-t2029, ST239-III-t421, ST1178-IV-t1107 and ST241-III-t363, respectively. Conclusions The study showed that both rifampicin and fusidic acid resistance was associated with mutational change in rpoB and fusA, respectively. All rifampicin-resistant strains were from the same clone ST239-III-t037 whereas strains resistant to fusidic acid were genetically more diverse

Image-guided Raman endoscopy for in vivo detection of high grade dysplasia in gastric

2009 Conference on Lasers and Electro-Optics and 2009 Conference on Quantum Electronics and Laser Science Conference, CLEO/QELS 2009

Real-world experiences of folic acid supplementation (5 versus 30 mg/week) with methotrexate in rheumatoid arthritis patients: a comparison study

The objective of this study was to compare the tolerability of methotrexate in two different regimes of folic acid (FA) supplementation in rheumatoid arthritis (RA). We performed a multicenter, cross-sectional observational cohort study on 240 RA patients with 120 patients each in 5 mg of FA weekly and 30 mg of FA weekly supplementation. There were no significant differences for side effects (14.2 versus 22.5%, P=0.523) and discontinuation of methotrexate (3.6 versus 13.3%, P=0.085). RA patients given 5 mg of FA weekly supplementation had a lower disease activity score 28 compared to 30 mg of FA weekly supplementation [3.44 (1.10) versus 3.85 (1.40), P=0.014]. FA supplementation of 5 mg per week and 30 mg per week was associated with similar tolerability of methotrexate in RA patients

CEACAM6 is upregulated by Helicobacter pylori CagA and is a biomarker for early gastric cancer

10.18632/oncotarget.10528Oncotarget73455290-5530

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Data were assessed overall and by WHO regions, sex, and index versus non-index cases. Findings Of the 61 612 individuals in the registry, 42 167 adults (21 999 [53·6%] women) from 56 countries were included in the study. Of these, 31 798 (75·4%) were diagnosed with the Dutch Lipid Clinic Network criteria, and 35 490 (84·2%) were from the WHO region of Europe. Median age of participants at entry in the registry was 46·2 years (IQR 34·3–58·0); median age at diagnosis of familial hypercholesterolaemia was 44·4 years (32·5–56·5), with 40·2% of participants younger than 40 years when diagnosed. Prevalence of cardiovascular risk factors increased progressively with age and varied by WHO region. Prevalence of coronary disease was 17·4% (2·1% for stroke and 5·2% for peripheral artery disease), increasing with concentrations of untreated LDL cholesterol, and was about two times lower in women than in men. Among patients receiving lipid-lowering medications, 16 803 (81·1%) were receiving statins and 3691 (21·2%) were on combination therapy, with greater use of more potent lipid-lowering medication in men than in women. Median LDL cholesterol was 5·43 mmol/L (IQR 4·32–6·72) among patients not taking lipid-lowering medications and 4·23 mmol/L (3·20–5·66) among those taking them. Among patients taking lipid-lowering medications, 2·7% had LDL cholesterol lower than 1·8 mmol/L; the use of combination therapy, particularly with three drugs and with proprotein convertase subtilisin–kexin type 9 inhibitors, was associated with a higher proportion and greater odds of having LDL cholesterol lower than 1·8 mmol/L. Compared with index cases, patients who were non-index cases were younger, with lower LDL cholesterol and lower prevalence of cardiovascular risk factors and cardiovascular diseases (all p<0·001). Interpretation Familial hypercholesterolaemia is diagnosed late. Guideline-recommended LDL cholesterol concentrations are infrequently achieved with single-drug therapy. Cardiovascular risk factors and presence of coronary disease were lower among non-index cases, who were diagnosed earlier. Earlier detection and greater use of combination therapies are required to reduce the global burden of familial hypercholesterolaemia. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron